TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study presented at the 2026 EADV Congress found that people taking GLP-1 medications reported nail detachment and discoloration more often than people who had not used the drugs. The cross-sectional findings show an association, not proof of cause; researchers say patients should discuss changes with a clinician rather than stop treatment on their own.
A multinational study presented at the European Academy of Dermatology and Venereology Congress 2026 found that people taking GLP-1 medications reported nail detachment more often than people who had never used the drugs. The results also showed more nail discoloration among users, but the study does not establish that the medications caused the changes.
Researchers compared 575 people using GLP-1 medications with 1,329 people who had obesity and/or type 2 diabetes but had never used the drugs. Participants were recruited in France, the United States, Brazil and Mexico. The medications in the wider GLP-1 class include drugs used for diabetes and weight management, such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza and Trulicity.
In the study, 39% of GLP-1 users reported nail detachment, in which the nail separates from the skin underneath, compared with 9% of nonusers. Nail discoloration was reported by 46% of users and 17% of the comparison group. Overall, 66% of users reported at least one nail disorder, compared with 53% of nonusers.
The researchers said the difference was not explained entirely by weight loss: users who had lost weight still reported more nail problems than nonusers who had also lost weight. However, about half of the medication users said they had experienced nail problems before treatment. Adjusting for existing skin conditions and nutritional deficiencies narrowed some differences, though detachment and discoloration remained more common among users in the adjusted analyses.
Nail Changes May Merit a Check-In
The findings may help clinicians and patients recognize nail changes during GLP-1 treatment and discuss possible explanations. Nail detachment or discoloration can have causes other than medication, and the study cannot identify which factor explains an individual person’s symptoms. The results point to a possible association that warrants further study, not a reason to assume the drugs are responsible.
The researchers also reported related hair and scalp findings in the same participants: unusual hair loss was reported by 50% of users and 34% of nonusers, while scalp redness was about three times as frequent among users. These are reported symptoms from the study, not proof that treatment caused them. The researchers suggested scalp inflammation could be involved, but that possibility needs testing.
For people taking these medications, the practical message from the study authors was to raise new nail or scalp symptoms with a doctor. They cautioned against stopping an effective treatment without medical advice. People considering changes to a prescription should consult the clinician who manages their care, particularly if they have other health conditions or concerns about nutrition.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Navy
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
From Anecdotes to a Comparison
GLP-1 receptor agonists act on hormone signaling involved in blood sugar regulation and appetite. They are used in the treatment of type 2 diabetes and, for some medications, weight management. As their use has grown, researchers have examined possible effects beyond these intended metabolic outcomes.
Before this investigation, reports of nail changes during GLP-1 treatment were largely individual accounts, according to the study report. The researchers described their work as the first controlled study of the possible relationship between these medications and nail health. That distinction means the study compared groups, but it does not mean it tracked people from before treatment through after starting it.
The nail and companion hair findings came from cross-sectional research, which records participants’ experiences at a point in time rather than following them prospectively. The comparison group had obesity and/or diabetes, conditions that may themselves be relevant to health and symptoms. The results therefore add comparative evidence to earlier reports, while leaving questions about timing and cause unresolved.
““Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.””
— Dr. Charles Taïeb, study author
Cause and Timing Remain Unresolved
The study was cross-sectional, so it cannot show whether nail changes began after medication use or establish that the drugs caused them. Many users reported nail problems before starting treatment, and the report says other factors—including skin conditions and nutritional deficiencies—accounted for part of the difference between groups.
The available findings also do not specify the risk for each individual medication, whether particular doses or treatment durations are associated with symptoms, or how often reported nail changes were clinically confirmed. The study report does not provide enough detail to determine whether the same results would apply to all GLP-1 users. Larger studies that follow patients over time would be needed to clarify these questions.
Further Follow-Up Is Needed
The findings were presented at the EADV Congress 2026; the supplied report does not identify a next study milestone or say when further results will be published. Researchers would need to follow people before and after treatment begins, account for other possible causes, and assess symptoms clinically to test whether the association reflects a medication effect.
In the meantime, the study authors advise people who notice nail detachment, discoloration, hair shedding, or an itchy or red scalp to discuss the changes with a healthcare professional. Patients should not stop or alter prescribed GLP-1 treatment on their own; a clinician can assess symptoms and review the benefits and risks for that person’s situation.
Key Questions
What nail problems did the study report?
The researchers found more reports of nail detachment and discoloration among GLP-1 users. Detachment was reported by 39% of users and 9% of nonusers; discoloration was reported by 46% and 17%, respectively.
Does this prove GLP-1 drugs cause nail problems?
No. The study found an association, but its cross-sectional design cannot establish cause or show when symptoms began. Some users said their nail problems predated treatment.
Should someone stop taking a GLP-1 medication if their nails change?
The study authors advised people not to stop an effective treatment on their own. Anyone noticing nail changes should contact their healthcare professional to discuss the symptoms and treatment.
Were hair and scalp symptoms also reported?
Yes. In a companion analysis of the same participants, users more often reported unusual hair loss and scalp symptoms, including redness. Those findings also show group differences, not proof that medication caused them.
Source: rss
